Skip to main content
SpringerLink
Log in

Cardiovascular Risk-Benefit Profile of Sibutramine

  • Review Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Sibutramine is a combined norepinephrine and serotonin reuptake inhibitor used as an antiobesity agent to reduce appetite and promote weight loss in combination with diet and exercise. At a daily dose of 10–20 mg, it was initially considered to have a good safety profile, as it does not induce primary pulmonary hypertension or adverse effects on cardiac valves, in contrast to previous reports relating to some other antiobesity agents. However, it exerts disparate effects on cardiovascular risk factors. On the one hand, sibutramine may have antiatherogenic activities, as it improves insulin resistance, glucose metabolism, dyslipidemia, and inflammatory markers, with most of these effects resulting from weight loss rather than from an intrinsic effect of the drug. On the other hand, because of its specific mode of action, sibutramine exerts a peripheral sympathomimetic effect, which induces a moderate increase in heart rate and attenuates the reduction in BP attributable to weight loss or even slightly increases BP. It may also prolong the QT interval, an effect that could induce arrhythmias. Because of these complex effects, it is difficult to conclude what the final impact of sibutramine on cardiovascular outcomes might be. Sibutramine has been shown to exert favorable effects on some surrogate cardiovascular endpoints such as reduction of left ventricular hypertrophy and improvement of endothelial dysfunction. A good cardiovascular safety profile was demonstrated in numerous 1- to 2-year controlled trials, in both diabetic and nondiabetic well selected patients, as well as in several observational studies. However, since 2002, several cardiovascular adverse events (hypertension, tachycardia, arrhythmias, and myocardial infarction) have been reported in sibutramine-treated patients. This led to a contraindication of the use of this antiobesity agent in patients with established coronary heart disease, previous stroke, heart failure, or cardiac arrhythmias. SCOUT (Sibutramine Cardiovascular and Diabetes Outcome Study) was designed to prospectively evaluate the efficacy/safety ratio of sibutramine in a high-risk population. The efficacy/safety results of the first 6-week lead-in open period of treatment with sibutramine 10 mg/day were reassuring in 10 742 overweight/obese high-risk subjects (97% had cardiovascular disease, 88% had hypertension, and 84% had type 2 diabetes mellitus). However, the final results of SCOUT showed that long-term (5 years’) treatment with sibutramine (10–15 mg/day) exposed subjects with pre-existing cardiovascular disease to a significantly increased risk for nonfatal myocardial infarction and nonfatal stroke, but not cardiovascular death or all-cause mortality. Because the benefit of sibutramine as a weight-loss aid seems not to outweigh the cardiovascular risks, the European Medicines Agency recommended the suspension of marketing authorizations for sibutramine across the EU. The US FDA stated that the drug should carry a ‘black box’ warning due to an increased risk of stroke and heart attack in patients with a history of cardiovascular disease. In conclusion, concern still persists about the safety profile of sibutramine regarding cardiovascular outcomes, and the drug should not be prescribed for overweight/obese patients with a high cardiovascular risk profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hofbauer KG, Nicholson JR, Boss O. The obesity epidemic: current and future pharmacological treatments. Ann Rev Pharmacol Toxicol 2007; 47: 565–92.

    Article  CAS  Google Scholar 

  2. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004; 110: 2952–67.

    Article  PubMed  Google Scholar 

  3. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. An update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898–918.

    Article  PubMed  Google Scholar 

  4. Després JP, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28: 1039–49.

    Article  PubMed  CAS  Google Scholar 

  5. Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2003; 63: 1165–84.

    Article  PubMed  CAS  Google Scholar 

  6. Reisin E, Jack AV. Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches. Med Clin North Am 2009; 93: 733–51.

    Article  PubMed  CAS  Google Scholar 

  7. Mathieu P, Lemieux I, Després JP. Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther 2010; 87: 407–16.

    Article  PubMed  CAS  Google Scholar 

  8. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875–80.

    Article  PubMed  CAS  Google Scholar 

  9. Zalesin KC, Franklin BA, Miller WM, et al. Impact of obesity on cardiovascular disease. Endocrinol Metab Clin North Am 2008; 37: 663–84.

    Article  PubMed  CAS  Google Scholar 

  10. Douketis JD, Sharma AM. Obesity and cardiovascular disease: pathogenic mechanisms and potential benefits of weight reduction. Semin Vasc Med 2005; 5: 25–33.

    Article  PubMed  Google Scholar 

  11. Bodary PF, Iglay HB, Eitzman DT. Strategies to reduce vascular risk associated with obesity. Curr Vasc Pharmacol 2007; 5: 249–58.

    Article  PubMed  CAS  Google Scholar 

  12. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925–32.

    Article  PubMed  Google Scholar 

  13. Lloret-Linares C, Greenfield JR, Czernichow S. Effect of weight-reducing agents on glycaemic parameters and progression to type 2 diabetes: a review. Diabet Med 2008; 25: 1142–50.

    Article  PubMed  CAS  Google Scholar 

  14. Choussein S, Makri AA, Frangos CC, et al. Effect of antiobesity medications in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009; 11: 641–64.

    Article  PubMed  CAS  Google Scholar 

  15. Buse JB, Ginsberg HN, Bakris GL, et al., American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30: 162–72.

    Article  PubMed  CAS  Google Scholar 

  16. Scheen AJ. Integrated approach to treatment and prevention. In: Hofbauer KG, Keller U, Boss O, editors. Pharmacotherapy of obesity: options and alternatives. Boca Raton (FL): CRC Press, 2004: 449–63.

    Chapter  Google Scholar 

  17. Scheen AJ. The future of obesity: new drugs versus lifestyle interventions. Expert Opin Investig Drugs 2008; 17: 263–7.

    Article  PubMed  CAS  Google Scholar 

  18. Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs 2005; 65: 1391–418.

    Article  PubMed  CAS  Google Scholar 

  19. Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology 2007; 132: 2239–52.

    Article  PubMed  CAS  Google Scholar 

  20. Li M, Cheung BM. Pharmacotherapy for obesity. Br J Clin Pharmacol 2009; 68: 804–10.

    Article  PubMed  CAS  Google Scholar 

  21. Idelevich E, Kirch W, Schindler C. Current pharmacotherapeutic concepts for the treatment of obesity in adults. Ther Adv Cardiovasc Dis 2009; 3: 75–90.

    Article  PubMed  Google Scholar 

  22. Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med 2005; 143: 380–5.

    PubMed  Google Scholar 

  23. Heal DJ, Gosden J, Smith SL. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol 2009; 68: 861–74.

    Article  PubMed  CAS  Google Scholar 

  24. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products used in weight control, 1 Jun 2006 [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/ewp/028196en.pdf [Accessed 2010 Jul 18].

  25. Scheen AJ, Lefèbvre PJ. Pharmacological treatment of obesity: present status. Int J Obes 1999; 23 Suppl. 1: 47–53.

    Article  CAS  Google Scholar 

  26. Collins P, Williams G. Drug treatment of obesity: from past failures to future successes? Br J Clin Pharmacol 2001; 51: 13–25.

    Article  PubMed  CAS  Google Scholar 

  27. Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf 2005; 4: 1083–95.

    Article  PubMed  CAS  Google Scholar 

  28. Robinson JR, Niswender KD. What are the risks and the benefits of current and emerging weight-loss medications? Curr Diab Rep 2009; 9: 368–75.

    Article  PubMed  Google Scholar 

  29. McNeely W, Goa KL. Sibutramine: a review of its contribution in the management of obesity. Drugs 1998; 56: 1093–124.

    Article  PubMed  CAS  Google Scholar 

  30. Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 2000; 1: 127–39.

    Article  PubMed  CAS  Google Scholar 

  31. Sharma B, Henderson DC. Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother 2008; 9: 2161–73.

    Article  PubMed  CAS  Google Scholar 

  32. Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag 2009; 5: 441–52.

    PubMed  CAS  Google Scholar 

  33. Luque CA, Rey JA. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 2002; 440: 119–28.

    Article  PubMed  CAS  Google Scholar 

  34. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164: 994–1003.

    Article  PubMed  CAS  Google Scholar 

  35. Norris SL, Zhang X, Avenell A, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2004; 164: 1395–404.

    Article  PubMed  CAS  Google Scholar 

  36. Scheen AJ, Ernest Ph. Antiobesity treatment in type 2 diabetes: results of clinical trials with orlistat and sibutramine. Diabetes Metab 2002; 28: 437–45.

    PubMed  CAS  Google Scholar 

  37. Neovius M, Johansson K, Rössner S. Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and metaanalysis. Obes Rev 2008; 9: 420–7.

    Article  PubMed  CAS  Google Scholar 

  38. James WPT, Astrup A, Fier N et al., for the STORM Study Group. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356: 2119–25.

    Article  PubMed  CAS  Google Scholar 

  39. Scheen AJ, Paquot N. Pharmacological treatment of obesity, food intake, and reversal of metabolic disorders. Curr Nutr Food Sci 2007; 3: 123–33.

    Article  CAS  Google Scholar 

  40. Vettor R, Serra R, Fabris R, et al. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 2005; 28: 942–9.

    Article  PubMed  CAS  Google Scholar 

  41. Nisoli E, Carruba MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 2003; 26: 1027–48.

    Article  PubMed  CAS  Google Scholar 

  42. Ioannides-Demos LL, Proietto J, Tonkin AM, et al. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 2006; 29: 277–302.

    Article  PubMed  CAS  Google Scholar 

  43. Guven A, Koksal N, Cetinkaya A, et al. Effects of the sibutramine therapy on pulmonary artery pressure in obese patients. Diabetes Obes Metab 2004; 6: 50–5.

    Article  PubMed  CAS  Google Scholar 

  44. Bach DS, Rissanen AM, Mendel CM, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999; 7: 363–9.

    Article  PubMed  CAS  Google Scholar 

  45. Pereira JL, López-Pardo F, Parejo J, et al. Study of heart valve function in obese patients treated with sibutramine. Med Clin (Barc) 2002; 118: 57–9.

    Google Scholar 

  46. Narkiewicz K. Sibutramine and its cardiovascular profile. Int J Obes Relat Metab Disord 2002; 26 Suppl. 4: S38–41.

    Article  PubMed  CAS  Google Scholar 

  47. de Simone G, Romano C, De Caprio C, et al. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects. Nutr Metab Cardiovasc Dis 2005; 15: 24–30.

    Article  PubMed  Google Scholar 

  48. de Simone G, D’Addeo G. Sibutramine: balancing weight loss benefit and possible cardiovascular risk. Nutr Metab Cardiovasc Dis 2008; 18: 337–41.

    Article  PubMed  CAS  Google Scholar 

  49. Chaput JP, Berube-Parent S, Tremblay A. Obesity and cardiovascular physiology: impact of some pharmacological agents. Curr Vasc Pharmacol 2005; 3: 185–93.

    Article  PubMed  CAS  Google Scholar 

  50. Kim SH, Lee YM, Jee SH, et al. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003; 11: 1116–23.

    Article  PubMed  CAS  Google Scholar 

  51. Filippatos TD, Kiotsis DN, Liberopoulos EN, et al. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005; 21: 457–68.

    Article  PubMed  CAS  Google Scholar 

  52. Mannucci E, Dicembrini I, Rotella F, et al. Orlistat and sibutramine beyond weight loss. Nutr Metab Cardiovasc Dis 2008; 18: 342–8.

    Article  PubMed  CAS  Google Scholar 

  53. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194–9.

    Article  PubMed  CAS  Google Scholar 

  54. Faria AN, Ribeiro Filho FF, Kohlmann NE, et al. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. Diabetes Obes Metab 2005; 7: 246–53.

    Article  PubMed  CAS  Google Scholar 

  55. Valsamakis G, McTernan PG, Chetty R, et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004; 53: 430–4.

    Article  PubMed  CAS  Google Scholar 

  56. Jung SH, Park HS, Kim KS, et al. Effect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight loss. Nutr Biochem 2008; 19: 371–5.

    Article  CAS  Google Scholar 

  57. Bray GA. Sibutramine and blood pressure: a therapeutic dilemma. J Hum Hypertens 2002; 16: 1–3.

    Article  PubMed  CAS  Google Scholar 

  58. Haddock CK, Poston WS, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26: 262–73.

    Article  PubMed  CAS  Google Scholar 

  59. Horvath K, Jeitler K, Siering U, et al. Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Arch Intern Med 2008; 168: 571–80.

    Article  PubMed  CAS  Google Scholar 

  60. Johansson K, Sundström J, Neovius K, et al. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Obes Rev 2009 Dec 15. Epub ahead of print.

  61. Czernichow S, Lee CM, Barzi F, et al. Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials. Obes Rev 2010; 11: 150–8.

    Article  PubMed  CAS  Google Scholar 

  62. Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev 2008; 9: 378–87.

    Article  PubMed  CAS  Google Scholar 

  63. Scholze J, Grimm E, Herrmann D, et al. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 2007; 115: 1991–8.

    Article  PubMed  CAS  Google Scholar 

  64. Cook S, Togni M, Schaub MC, et al. High heart rate: a cardiovascular risk factor? Eur Heart J 2006; 27: 2387–93.

    Article  PubMed  Google Scholar 

  65. Haynes WG, Egri Z. Sibutramine and the sympathetic nervous system in obese humans. Clin Auton Res 2005; 15: 189–92.

    Article  PubMed  Google Scholar 

  66. Birkenfeld AL, Schroeder C, Boschmann M, et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 2002; 106: 2459–65.

    Article  PubMed  CAS  Google Scholar 

  67. Birkenfeld AL, Schroeder C, Pischon T, et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients: sibutramine and blood pressure. Clin Auton Res 2005; 15: 200–6.

    Article  PubMed  Google Scholar 

  68. Heusser K, Tank J, Diedrich A, et al. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther 2006; 79: 500–8.

    Article  PubMed  CAS  Google Scholar 

  69. Heusser K, Engeli S, Tank J, et al. Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. J Clin Endocrinol Metab 2007; 92: 1560–3.

    Article  PubMed  CAS  Google Scholar 

  70. Hirsch J, Mackintosh RM, Aronne LJ. The effects of drugs used to treat obesity on the autonomic nervous system. Obes Res 2000; 8: 227–33.

    Article  PubMed  CAS  Google Scholar 

  71. Quilliot D, Böhme P, Zannad F, et al. Sympathetic-leptin relationship in obesity: effect of weight loss. Metabolism 2008; 57: 555–62.

    Article  PubMed  CAS  Google Scholar 

  72. Duivenvoorden R, de Groot E, Stroes ES, et al. Surrogate markers in clinical trials: challenges and opportunities. Atherosclerosis 2009; 206: 8–16.

    Article  PubMed  CAS  Google Scholar 

  73. Frick M, Weidinger F. Endothelial function: a surrogate endpoint in cardiovascular studies? Curr Pharm Des 2007; 13: 1741–50.

    Article  PubMed  CAS  Google Scholar 

  74. Verdecchia P, Angeli F, Borgioni C, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16: 895–9.

    Article  PubMed  Google Scholar 

  75. Zannad F, Gille B, Grentzinger A, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002; 144: 508–15.

    Article  PubMed  CAS  Google Scholar 

  76. Wirth A, Scholze J, Sharma AM, et al. Reduced left ventricular mass after treatment of obese patients with sibutramine: an echocardiographic multi-centre study. Diabetes Obes Metab 2006; 8: 674–81.

    Article  PubMed  CAS  Google Scholar 

  77. Shechter M, Beigel R, Freimark D, et al. Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease. Am J Cardiol 2006; 97: 1650–3.

    Article  PubMed  CAS  Google Scholar 

  78. de Groot E, van Leuven SI, Duivenvoorden R, et al. Measurement of carotid intima-media thickness to assess progression and regression of atherosclerosis. Nat Clin Pract Cardiovasc Med 2008; 5: 280–8.

    Article  PubMed  Google Scholar 

  79. Bosello O, Carruba MO, Ferrannini E, et al. Sibutramine lost and found. Eat Weight Disord 2002; 7: 161–7.

    PubMed  CAS  Google Scholar 

  80. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 2002; 166: 1307–8.

    PubMed  Google Scholar 

  81. Johansson K, Neovius K, DeSantis SM, et al. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev 2009; 10: 564–75.

    Article  PubMed  CAS  Google Scholar 

  82. Patel MR, Donahue M, Wilson PW, et al. Clinical trial issues in weight-loss therapy. Am Heart J 2006; 151: 633–42.

    Article  PubMed  Google Scholar 

  83. Perrio MJ, Wilton LV, Shakir SA. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity (Silver Spring) 2007; 15: 2712–22.

    Article  Google Scholar 

  84. Gaciong Z, Placha G. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study. J Hum Hypertension 2005; 19: 737–43.

    Article  CAS  Google Scholar 

  85. Seebeck J, Wulf F, Sachs B. Label-inconsistent use of sibutramine in spontaneous adverse drug reaction reports in Germany. Int J Clin Pharmacol Ther 2008; 46: 375–81.

    PubMed  CAS  Google Scholar 

  86. Dahlin A, Beermann B. Incorrect use of orlistat and sibutramine in clinical practice. Eur J Clin Pharmacol 2007; 63: 205–9.

    Article  PubMed  Google Scholar 

  87. Harrison-Woolrych M, Ashton J, Herbison P. Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine: a prospective cohort study. Drug Safety 2010; 33: 605–13.

    Article  PubMed  Google Scholar 

  88. Scheen AJ. Controversy about the cardiovascular safety of sibutramine. Drug Safety 2010; 33: 615–8.

    Article  PubMed  Google Scholar 

  89. Harrison-Woolrych M, Clark DW, Hill GR, et al. QT interval prolongation associated with sibutramine treatment. Br J Clin Pharmacol 2006; 61: 464–9.

    Article  PubMed  CAS  Google Scholar 

  90. Yalcin AA, Yavuz B, Ertugrul DT, et al. Elevation of QT dispersion after obesity drug sibutramine. J Cardiovasc Med (Hagerstown). 2010 Jul 27. Epub ahead of print.

  91. Ernest D, Gershenzon A, Corallo CE, et al. Sibutramine-associated QT interval prolongation and cardiac arrest. Ann Pharmacother 2008; 42: 1514–7.

    Article  PubMed  CAS  Google Scholar 

  92. Kim KS, Kim EJ, Lee HA, et al. Effect of sibutramine HCl on cardiac hERG K+ channel. Mol Cell Biochem 2009; 320: 125–31.

    Article  PubMed  CAS  Google Scholar 

  93. Azarisman SM, Magdi YA, Noorfaizan S, et al. Myocardial infarction induced by appetite suppressants in Malaysia. N Engl J Med 2007; 357: 1873–4.

    Article  PubMed  CAS  Google Scholar 

  94. Yim KM, Ng HW, Chan CK, et al. Sibutramine-induced acute myocardial infarction in a young lady. Clin Toxicol (Phila) 2008; 46: 877–9.

    Article  CAS  Google Scholar 

  95. Eroglu E, Gemici G, Bayrak F, et al. Acute myocardial infarction in a 24 year-old man possibly associated with sibutramine use. Int J Cardiol 2009; 137: e43–5.

    Article  PubMed  Google Scholar 

  96. Gómez-Barrado JJ, Turégano S, Garcipérez de Vargas FJ, et al. Acute coronary syndrome in a young woman treated with sibutramine [letter]. Rev Esp Cardiol 2010; 63: 242–3.

    Google Scholar 

  97. Sayin T, Güldal M. Sibutramine: possible cause of a reversible cardiomyopathy. Int J Cardiol 2005; 99: 481–2.

    Article  PubMed  Google Scholar 

  98. Kim KA, Song WK, Park JY. Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. Clin Pharmacol Ther 2009; 86: 511–8.

    Article  PubMed  CAS  Google Scholar 

  99. Chung JY, Jang SB, Lee YJ, et al. Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. J Clin Pharmacol 2010 Mar 29. Epub ahead of print.

  100. Tomalik-Scharte D, Lazar A, Fuhr U, et al. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 2008; 8: 4–15.

    Article  PubMed  CAS  Google Scholar 

  101. Minns AB, Ebrahimi S, Te L, et al. A retrospective review of California poison control system data of sibutramine exposures. Clin Toxicol (Phila) 2009; 47: 814–7.

    Article  CAS  Google Scholar 

  102. James WPT. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J 2005; 7(Suppl. L): L44–8.

    CAS  Google Scholar 

  103. Torp-Pedersen C, Caterson I, Coutinho W, et al., SCOUT Investigators. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007; 28: 2915–23.

    Article  PubMed  Google Scholar 

  104. Sharma AM, Caterson ID, Coutinho W, et al., SCOUT Investigators. Blood pressure changes associated with sibutramine and weight management: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes Obes Metab 2009; 11: 239–50.

    Article  PubMed  CAS  Google Scholar 

  105. Van Gaal LF, Caterson ID, Coutinho W, et al., SCOUT Investigators. Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. Diabetes Obes Metab 2010; 12: 26–34.

    Article  PubMed  Google Scholar 

  106. Weeke P, Andersson C, Fosbøl EL, et al. The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus: an analysis from the SCOUT lead-in period. BMC Endocr Disord 2010; 10: 3 doi:10.1186/1472-6823-10-3.

    Article  PubMed  CAS  Google Scholar 

  107. Maggioni AP, Caterson I, Coutinho W, et al., SCOUT Investigators. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. J Cardiovasc Pharmacol 2008; 52: 393–402.

    Article  PubMed  CAS  Google Scholar 

  108. Caterson I, Coutinho W, Finer N, et al., for the SCOUT Investigators. Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity (Silver Spring) 2010; 18: 987–94.

    Article  CAS  Google Scholar 

  109. Andersson C, Weeke P, Brendorp B, et al. Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial. Nutr Metab 2009; 6:42.

    Article  CAS  Google Scholar 

  110. von Haehling S, Lainscak M, Anker SD. Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon? Eur Heart J 2007; 28: 2830–1.

    Article  Google Scholar 

  111. James WPT, Caterson ID, Coutinho W, et al., for the SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905–17.

    Article  PubMed  CAS  Google Scholar 

  112. Williams G. Withdrawal of sibutramine in Europe. BMJ 2010 Feb 9; 340: c824. doi: 10.1136/bmj.c824.

    Article  PubMed  Google Scholar 

  113. European Medicines Agency. European Medicines Agency recommends suspension of marketing autorisation for sibutramine [online]. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl = pages/news_and_events/news/2 [Accessed 2010 Jul 18].

  114. US Food and Drug Administration. Meridia (sibutramine hydrochloride): follow-up to an early communication about an ongoing safety review [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/Safety Information/SafetyAlertsforHumanMedicalProducts/ucm198221.htm [Accessed 2010 Jul 18].

Download references

Acknowledgments

A.J. Scheen has no conflicts of interest directly related to this review, but was an investigator in the SCOUT trial. No funding was received for the preparation of this review.

Author information

Authors and Affiliations

  1. Division of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, Department of Medicine, University of Liège, CHU Sart Tilman (B35), B-4000, Liège, Belgium

    André J. Scheen

Authors
  1. André J. Scheen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to André J. Scheen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scheen, A.J. Cardiovascular Risk-Benefit Profile of Sibutramine. Am J Cardiovasc Drugs 10, 321–334 (2010). https://doi.org/10.2165/11584800-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11584800-000000000-00000

Keywords

Search

Navigation